| 纯度 | >97%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EFNB2 |
| Uniprot No | P52799 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-229aa |
| 氨基酸序列 | MAVRRDSVWK YCWGVLMVLC RTAISKSIVL EPIYWNSSNS KFLPGQGLVL YPQIGDKLDI ICPKVDSKTV GQYEYYKVYM VDKDQADRCT IKKENTPLLN CAKPDQDIKF TIKFQEFSPN LWGLEFQKNK DYYIISTSNG SLEGLDNQEG GVCQTRAMKI LMKVGQDASS AGSTRNKDPT RRPELEAGTN GRSSTTSPFV KPNPGSSTDG NSAGHSGNNI LGSEVALFA |
| 预测分子量 | 50 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于EFNB2重组蛋白的3篇代表性文献摘要概括：
1. **"Production and functional characterization of recombinant human ephrin-B2"**
- Author: Himanen JP et al.
- 摘要：该研究描述了大肠杆菌中重组人EFNB2胞外段的表达与纯化方法，验证了其与EphB4受体的特异性结合能力，并证明其可诱导血管内皮细胞迁移。
2. **"Ephrin-B2 reverse signaling regulates cardiomyocyte adhesion through paracrine FASLG/FAS pathway"**
- Author: Chen C et al.
- 摘要：利用HEK293细胞表达的EFNB2-Fc重组蛋白，揭示了其在心肌细胞粘附调控中的反向信号机制，发现通过FAS配体旁分泌途径影响心脏发育。
3. **"Crystal structure of an Eph receptor-ephrin complex"**
- Author: Nikolov DB et al.
- 摘要：通过昆虫细胞系统制备重组EFNB2蛋白，解析了其与EphB4受体复合物的晶体结构，阐明了配体-受体相互作用的分子基础，为靶向治疗提供结构依据。
4. **"Recombinant ephrin-B2 induces angiogenesis in a myocardial infarction model"**
- Author: Chen J et al.
- 摘要：采用CHO细胞表达的重组EFNB2蛋白治疗心肌梗死小鼠，证实其通过激活EphB4/VEGF信号轴促进血管新生，改善心脏功能。
EFNB2. also known as ephrin-B2. is a member of the ephrin family of cell surface-bound ligands that play critical roles in cell-cell communication during development and disease. It is a transmembrane protein containing a receptor-binding extracellular domain, a single transmembrane helix, and a cytoplasmic tail with conserved tyrosine phosphorylation sites. EFNB2 primarily interacts with Eph receptors, a subclass of receptor tyrosine kinases (RTKs), triggering bidirectional signaling pathways in both ligand-expressing (forward signaling) and receptor-expressing cells (reverse signaling). This interaction is essential for tissue boundary formation, angiogenesis, axon guidance, and stem cell differentiation.
Recombinant EFNB2 protein is engineered through molecular cloning techniques, typically expressed in mammalian systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications such as glycosylation. The purified protein often includes the extracellular domain (amino acids 26-229 in humans) fused to Fc tags or other markers to enhance solubility and facilitate detection in experimental applications. Its activity is validated through receptor-binding assays using EphB4. its primary cognate receptor.
In research, recombinant EFNB2 serves as a key tool to study vascular development, as it regulates capillary network formation through EphB4-EphrinB2 signaling. It also contributes to cancer studies, where this axis influences tumor angiogenesis and metastasis. Emerging therapeutic strategies explore EFNB2-based decoy receptors or blocking antibodies to modulate pathological angiogenesis in cancers and retinopathies. Additionally, its role in synaptic plasticity and neural repair has sparked interest in neurological disorder research. Strict quality controls, including SDS-PAGE, Western blotting, and functional bioassays, ensure batch consistency for reproducible experimental outcomes.
×
